EYEPOINT PHARMACEUTICALS INC. - COMMON STOCK

EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025

30 أبريل 2025 07:00:00 بحسب Nasdaq GlobeNewswire

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

16 أبريل 2025 07:00:00 بحسب Nasdaq GlobeNewswire

EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference

27 مارس 2025 07:00:00 بحسب Nasdaq GlobeNewswire

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

17 مارس 2025 07:00:00 بحسب Nasdaq GlobeNewswire

EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments

05 مارس 2025 07:00:00 بحسب Nasdaq GlobeNewswire

EyePoint Announces Participation at Upcoming Investor Conferences

04 مارس 2025 07:00:00 بحسب Nasdaq GlobeNewswire

EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025

26 فبراير 2025 07:00:00 بحسب Nasdaq GlobeNewswire

EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference

25 فبراير 2025 07:00:00 بحسب Nasdaq GlobeNewswire

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

17 فبراير 2025 07:00:00 بحسب Nasdaq GlobeNewswire

EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema Meeting Primary and Secondary Endpoints

05 فبراير 2025 07:00:00 بحسب Nasdaq GlobeNewswire

EyePoint to Present at Guggenheim SMID Cap Biotech Conference

30 يناير 2025 07:00:00 بحسب Nasdaq GlobeNewswire

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

16 يناير 2025 07:00:00 بحسب Nasdaq GlobeNewswire